<DOC>
	<DOCNO>NCT00565279</DOCNO>
	<brief_summary>A grow body evidence support hypothesis pathophysiology seborrhoeic dermatitis potentially causative neurogenic inflammatory aspect . ASF1057 new drug act modulation neurogenic inflammation important complementary mechanism action . This study test efficacy safety ASF1057 treatment patient seborrhoeic dermatitis .</brief_summary>
	<brief_title>Efficacy Safety ASF1057 Treatment Seborrhoeic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Seborrheic</mesh_term>
	<criteria>Clinical diagnosis moderate severe seborrhoeic dermatitis Other active skin disease Use certain systemic topical treatment Extensive sun exposure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Seborrhoeic dermatitis</keyword>
</DOC>